{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T02:29:19Z","timestamp":1654568959769},"reference-count":0,"publisher":"Hogrefe Publishing Group","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p> Zusammenfassung. Meningeome sind die h\u00e4ufigsten hirneigenen Tumoren und haben eine medizinische Relevanz in der Hausarztmedizin. Diese Tumoren sind \u00fcberwiegend gutartig (WHO-Grad I) und k\u00f6nnen entweder beobachtet oder operiert werden. Bei einer kompletten Tumorentfernung ist das R\u00fcckfallrisiko gering. H\u00f6her-gradige Meningeome (WHO-Grad II\/III) bed\u00fcrfen meist einer multimodalen Therapie mit Operation und Strahlentherapie, auch wenn hierzu keine kontrollierten Studien vorliegen. Das Rezidivrisiko dieser Meningeome ist wesentlich h\u00f6her, sodass engmaschiger mittels kranialer Magnetresonanztomografie nachuntersucht werden muss, um Rezidive fr\u00fch zu entdecken. Neue Systemtherapien mit gezieltem Wirkmechanismus (\u00abtargeted drugs\u00bb) erweitern das therapeutische Spektrum und kommen zum Einsatz, wenn die lokalen Therapieverfahren versagen (z.B. Bevacizumab, Sunitinib). Bei Meningeomen aller WHO-Grade empfiehlt sich die Festlegung einer therapeutischen Strategie im Rahmen eines interdisziplin\u00e4ren Tumorboards. <\/jats:p>","DOI":"10.1024\/1661-8157\/a002320","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T16:52:45Z","timestamp":1460652765000},"page":"445-451","source":"Crossref","is-referenced-by-count":2,"title":["Das Meningeom: Management des h\u00e4ufigsten hirneigenen Tumors"],"prefix":"10.1024","volume":"105","author":[{"given":"Thomas","family":"Hundsberger","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Neurologie, Kantonsspital St. Gallen"},{"name":"Klinik f\u00fcr H\u00e4matologie und Onkologie, Kantonsspital St. Gallen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Surbeck","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Neurochirurgie, Kantonsspital St. Gallen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Hader","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Radiologie und Nuklearmedizin, Kantonsspital St. Gallen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Martin","family":"Putora","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Radioonkologie, Kantonsspital St. Gallen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Conen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Onkologie, Universit\u00e4tsspital Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Roelcke","sequence":"additional","affiliation":[{"name":"Neurologische Klinik und Hirntumorzentrum, Kantonsspital Aarau"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a002320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T17:29:53Z","timestamp":1615915793000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a002320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1024\/1661-8157\/a002320"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a002320","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}